Literature DB >> 28741059

Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis.

Leila Sisic1, Moritz J Strowitzki1, Susanne Blank1, Henrik Nienhueser1, Sara Dorr1, Georg Martin Haag2, Dirk Jäger2, Katja Ott3, Markus W Büchler1, Alexis Ulrich1, Thomas Schmidt4.   

Abstract

BACKGROUND: To date there is no evidence that more intensive follow-up after surgery for esophagogastric adenocarcinoma translates into improved survival. This study aimed to evaluate the impact of standardized surveillance by a specialized center after resection on survival.
METHODS: Data of 587 patients were analyzed who underwent curative surgery for esophagogastric adenocarcinoma in our institution. Based on their postoperative surveillance, patients were assigned to either standardized follow-up (SFU) by the National Center for Tumor Diseases (SFU group) or individual follow-up by other physicians (non-SFU group). Propensity score matching (PSM) was performed to compensate for heterogeneity between groups. Groups were compared regarding clinicopathological findings, recurrence, and impact on survival before and after PSM.
RESULTS: Of 587 patients, 32.7% were in the SFU and 67.3% in the non-SFU group. Recurrence occurred in 39.4% of patients and 92.6% within the first 3 years; 73.6% were treated, and of those 17.1% underwent resection. In recurrent patients overall and post-recurrence survival (OS/PRS) was influenced by diagnostic tools (p < 0.05), treatment (p ≤ 0.001), and resection of recurrence (p ≤ 0.001). Standardized follow-up significantly improved OS (84.9 vs. 38.4 months, p = 0.040) in matched analysis and was an independent positive predictor of OS before and after PSM (p = 0.034/0.013, respectively).
CONCLUSION: After PSM, standardized follow-up by a specialized center significantly improved OS. Cross-sectional imaging and treatment of recurrence were associated with better outcome. Regular follow-up by cross-sectional imaging especially during the first 3 years should be recommended by national guidelines, since early detection might help select patients for treatment of recurrence and even resection in few designated cases.

Entities:  

Keywords:  Esophageal cancer; Follow-up; Gastric cancer; Prognosis; Recurrence

Mesh:

Year:  2017        PMID: 28741059     DOI: 10.1007/s10120-017-0751-4

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  73 in total

1.  Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis.

Authors:  Gaya Spolverato; Aslam Ejaz; Yuhree Kim; Malcolm H Squires; George A Poultsides; Ryan C Fields; Carl Schmidt; Sharon M Weber; Konstantinos Votanopoulos; Shishir K Maithel; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2014-06-26       Impact factor: 6.113

2.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

3.  The prognostic value of detecting symptomatic or asymptomatic recurrence in patients with gastric cancer after a curative gastrectomy.

Authors:  Ahmet Bilici; Tarik Salman; Bala Basak Oven Ustaalioglu; Tugba Unek; Mesut Seker; Mehmet Aliustaoglu; Cem Gezen; Tarkan Unek; Dilek Yavuzer; Mehtat Unlu; Mahmut Gumus; Ugur Yilmaz
Journal:  J Surg Res       Date:  2012-04-11       Impact factor: 2.192

4.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

5.  Follow-up strategy after curative resection of gastric cancer: a nationwide survey in Korea.

Authors:  Hoon Hur; Kyo Young Song; Cho Hyun Park; Hae Myung Jeon
Journal:  Ann Surg Oncol       Date:  2009-09-24       Impact factor: 5.344

6.  Attempted salvage resection for recurrent gastric or gastroesophageal cancer.

Authors:  Brian Badgwell; Janice N Cormier; Yan Xing; James Yao; Debashish Bose; Sunil Krishnan; Peter Pisters; Barry Feig; Paul Mansfield
Journal:  Ann Surg Oncol       Date:  2008-11-05       Impact factor: 5.344

7.  Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results.

Authors:  Long Sun; Xin-Hui Su; Yong-Song Guan; Wei-Ming Pan; Zuo-Ming Luo; Ji-Hong Wei; Hua Wu
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

8.  Risk factors of peritoneal recurrence in eso-gastric signet ring cell adenocarcinoma: results of a multicentre retrospective study.

Authors:  C Honoré; D Goéré; M Messager; A Souadka; F Dumont; G Piessen; D Elias; C Mariette
Journal:  Eur J Surg Oncol       Date:  2013-01-11       Impact factor: 4.424

9.  Detecting recurrence of gastric cancer: the value of FDG PET/CT.

Authors:  Min Jung Park; Won Jae Lee; Hyo K Lim; Ko Woon Park; Joon Young Choi; Byung-Tae Kim
Journal:  Abdom Imaging       Date:  2009-07

10.  The pattern and risk factors of recurrence of proximal gastric cancer after curative resection.

Authors:  Fangxuan Li; Rupeng Zhang; Han Liang; Hui Liu; Jichuan Quan
Journal:  J Surg Oncol       Date:  2012-09-04       Impact factor: 3.454

View more
  8 in total

1.  [Follow-up care for gastrointestinal tumors].

Authors:  M Ebert
Journal:  Internist (Berl)       Date:  2018-05       Impact factor: 0.743

Review 2.  [Therapeutic approach in oligometastatic gastric and esophageal cancer].

Authors:  T Schmidt; S P Mönig
Journal:  Chirurg       Date:  2017-12       Impact factor: 0.955

3.  VEGFA and VEGFR2 RNAscope determination in gastric cancer.

Authors:  Roberto Tamma; Tiziana Annese; Simona Ruggieri; Andrea Marzullo; Beatrice Nico; Domenico Ribatti
Journal:  J Mol Histol       Date:  2018-05-14       Impact factor: 2.611

Review 4.  Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.

Authors:  Henrik Nienhüser; Thomas Schmidt
Journal:  Int J Mol Sci       Date:  2017-12-23       Impact factor: 5.923

5.  Antipsychotic use is inversely associated with gastric cancer risk: A nationwide population-based nested case-control study.

Authors:  Yi-Hsuan Hsieh; Hsiang-Lin Chan; Chiao-Fan Lin; Sophie Hsin-Yi Liang; Mong-Liang Lu; Roger S McIntyre; Yena Lee; Tzu-Chin Lin; Wei-Che Chiu; Vincent Chin-Hung Chen
Journal:  Cancer Med       Date:  2019-06-10       Impact factor: 4.452

Review 6.  Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach.

Authors:  Jin-On Jung; Henrik Nienhüser; Nikolai Schleussner; Thomas Schmidt
Journal:  Int J Mol Sci       Date:  2020-01-31       Impact factor: 5.923

7.  Association of Risperidone With Gastric Cancer: Triangulation Method From Cell Study, Animal Study, and Cohort Study.

Authors:  Vincent Chin-Hung Chen; Tsai-Ching Hsu; Chiao-Fan Lin; Jing-Yu Huang; Yi-Lung Chen; Bor-Show Tzang; Roger S McIntyre
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

8.  Clinical Relevance of Gastroesophageal Cancer Associated SNPs for Oncologic Outcome After Curative Surgery.

Authors:  Jin-On Jung; Naita Maren Wirsik; Henrik Nienhüser; Leila Peters; Beat Peter Müller-Stich; Timo Hess; Vitalia Schüller; Johannes Schumacher; Thomas Schmidt
Journal:  Ann Surg Oncol       Date:  2021-09-16       Impact factor: 5.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.